VADUZ, Liechtenstein, Feb. 1, 2024 /PRNewswire/ — Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, reports that seven new scientific data presentations and abstracts on RefluxStop™ have been accepted at the Society of American…
Month: February 2024
VADUZ, Liechtenstein, Feb. 1, 2024 /PRNewswire/ — Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, reports that seven new scientific data presentations and abstracts on RefluxStop™ have been accepted at the Society of American…
NEW YORK, Feb. 1, 2024 /PRNewswire/ — The third-party chemical distribution market size is expected to grow by USD 121.73 million between 2022 and 2027. The growth momentum of the market will be progressing at a CAGR of 7.6% during the forecast period. The market is segmented by Type…
NEW YORK, Feb. 1, 2024 /PRNewswire/ — The third-party chemical distribution market size is expected to grow by USD 121.73 million between 2022 and 2027. The growth momentum of the market will be progressing at a CAGR of 7.6% during the forecast period. The market is segmented by Type…
CHICAGO, Feb. 1, 2024 /PRNewswire/ — Automotive Smart Antenna Market is estimated to grow from USD 2.5 billion in 2023 to USD 5.2 billion by 2030, at a CAGR of 10.9%, according to a new report by MarketsandMarkets™. The increased demand for connected car features, in-vehicle…
CHICAGO, Feb. 1, 2024 /PRNewswire/ — Automotive Smart Antenna Market is estimated to grow from USD 2.5 billion in 2023 to USD 5.2 billion by 2030, at a CAGR of 10.9%, according to a new report by MarketsandMarkets™. The increased demand for connected car features, in-vehicle…
First Phase 3 Results Published for an Allogeneic T-Cell Therapy Significant 51.2% Objective Response Rate and 23.0 Month Median Duration of Response in Relapsed or Refractory EBV+ PTLD Patients U.S. BLA on Track for Submission in Q2 2024 Based on Strong Clinical File CASTRES, France and…
First Phase 3 Results Published for an Allogeneic T-Cell Therapy Significant 51.2% Objective Response Rate and 23.0 Month Median Duration of Response in Relapsed or Refractory EBV+ PTLD Patients U.S. BLA on Track for Submission in Q2 2024 Based on Strong Clinical File CASTRES, France and…
Il s’agit des premiers résultats de phase III publiés pour une thérapie allogénique à cellules T Taux de réponse objective significatif de 51,2 % et durée médiane de la réponse de 23,0 mois chez les patients atteints de LPT EBV+ récidivante ou réfractaire La demande d’homologation d’un…
Il s’agit des premiers résultats de phase III publiés pour une thérapie allogénique à cellules T Taux de réponse objective significatif de 51,2 % et durée médiane de la réponse de 23,0 mois chez les patients atteints de LPT EBV+ récidivante ou réfractaire La demande d’homologation d’un…